Locate Bio is developing LDGraft™, a rhBMP-2 product currently in clinical trials for lumbar interbody fusion procedures, which has received FDA Breakthrough Device designation for the Anterior Lumbar Interbody Fusion indication. This technology aims to enhance spinal fusion outcomes for patients with degenerative disc disease by improving bone regeneration and integration.
Funding
$11.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Spinal fusion procedures for degenerative disc disease often face challenges in achieving robust bone regeneration and integration, potentially leading to suboptimal patient outcomes and the need for revision surgeries. Current bone graft options may lack the necessary osteoinductive properties or require large quantities, increasing the risk of complications.
Solution
Locate Bio is developing LDGraft™, a recombinant human bone morphogenetic protein-2 (rhBMP-2) product designed to enhance bone fusion in lumbar interbody fusion procedures. LDGraft™ aims to improve spinal fusion outcomes by promoting more effective bone regeneration and integration at the fusion site. The product is currently undergoing clinical trials and has received FDA Breakthrough Device designation for the Anterior Lumbar Interbody Fusion (ALIF) indication, specifically for one level from L3-S1 in patients with degenerative disc disease. This designation is intended to expedite the development and review of medical devices that offer a more effective treatment for life-threatening or irreversibly debilitating diseases or conditions.
Target Audience
The primary target audience includes spine surgeons and hospitals performing lumbar interbody fusion procedures for patients with degenerative disc disease.
Features
- rhBMP-2 formulation designed to stimulate bone growth and fusion.
- Investigational device for lumbar interbody fusion procedures.
- FDA Breakthrough Device designation for ALIF indication at one level from L3-S1 for patients with degenerative disc disease.